SERPINC1 and thrombophilia: As shown in Tables 3, 4 (pre rows), the results suggest that apixaban and rivaroxaban did not affect the thrombophilia tests (protein C, protein S and ATIII) as the mean values of these parameters with the addition of the DOAC are related to the controls without the DOAC and remained within the abnormal range.